Aichi, Japan

Shin-ishi Sakemi

This inventor holds 1 USPTO granted patent. Top assignee: Repligen Corporation. Active years: 1991.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shin-ishi Sakemi. Retrieved from https://idiyas.com/inventor/shin-ishi-sakemi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1991

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Shin-ishi Sakemi

Introduction

Shin-ishi Sakemi is a notable inventor based in Aichi, Japan. He has made significant contributions to the field of chemistry, particularly in the discovery of novel compounds with potential therapeutic applications. His work focuses on the isolation and characterization of unique alkaloids derived from marine sponges.

Latest Patents

Sakemi holds a patent for "Novel pyrroloquinoline alkaloids and methods of use." This invention pertains to novel compounds known as batzellines and isobatzellines, which have been isolated from marine sponges. These compounds have demonstrated antitumor activity, making them of great interest in the field of cancer research. Various derivatives of these compounds have been prepared, and the procedures for their isolation and preparation are detailed in his patent. He has 1 patent to his name.

Career Highlights

Sakemi is currently associated with Repligen Corporation, where he continues to advance his research in the field of biochemistry. His work has contributed to the understanding of marine-derived compounds and their potential applications in medicine.

Collaborations

He has collaborated with H Howard Sun, further enhancing the scope and impact of his research endeavors.

Conclusion

Shin-ishi Sakemi's innovative work in the field of chemistry highlights the importance of marine-derived compounds in medical research. His contributions continue to pave the way for new therapeutic options in the fight against cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…